APA

Kwak E. L., Shapiro G. I., Cohen S. M., Becerra C. R., Lenz H., Cheng W., Su W., Robohn M., Le Maulf F., Lobmeyer M. T., Chand V. K. & Iafrate A. J. (20140225). Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. : Cancer.

Chicago

Kwak Eunice L, Shapiro Geoffrey I, Cohen Seth M, Becerra Carlos R, Lenz Heinz-Josef, Cheng Wen-Fang, Su Wu-Chou, Robohn Meghan, Le Maulf Florence, Lobmeyer Maximilian T, Chand Vikram K and Iafrate A John. 20140225. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. : Cancer.

Harvard

Kwak E. L., Shapiro G. I., Cohen S. M., Becerra C. R., Lenz H., Cheng W., Su W., Robohn M., Le Maulf F., Lobmeyer M. T., Chand V. K. and Iafrate A. J. (20140225). Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. : Cancer.

MLA

Kwak Eunice L, Shapiro Geoffrey I, Cohen Seth M, Becerra Carlos R, Lenz Heinz-Josef, Cheng Wen-Fang, Su Wu-Chou, Robohn Meghan, Le Maulf Florence, Lobmeyer Maximilian T, Chand Vikram K and Iafrate A John. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. : Cancer. 20140225.